Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...
Hosted on MSN
Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results , with sales up 14.8% year on year to $182.4 million. The company’s full-year revenue guidance of $725 ...
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q4 CY2025 results exceeding the market’s revenue expectations , with sales up 18.1% year on year to $197.9 million. The ...
What: After reporting third quarter financial results, updating investors on its outlook, and receiving a Wall Street downgrade, shares in Repligen Corporation tumbled by nearly 20% today. So what: In ...
Shares of the bioprocessing giant Repligen Corporation (NASDAQ: RGEN) are glowing green today. Specifically, the biotech's stock was up by as much as 14.9% earlier today. Repligen's shares have cooled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results